Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations Within the Kinase Domain and Truncations of the Epidermal Growth Factor Receptor Are Rare Events in Bladder Cancer: Implications for Therapy

1 Aug 2006

Abstract excerpt

PURPOSE: It has previously been reported that the patient response to gefitinib depends on the presence of mutations within the kinase domain of epidermal growth factor receptor (EGFR) or the expression of its truncated form, EGFR variant III (EGFRvIII). The focus of this study was to determine if these alterations are present within the tyrosine kinase and ligand-binding domain of EGFR in urothelial carcinoma....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to Fibroblast Growth Factor Research
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16899617
DOI: 10.1158/1078-0432.ccr-06-0407

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations Within the Kinase Domain and Truncations of the Epidermal Growth Factor Receptor Are Rare Events in Bladder Cancer: Implications for TherapyPMID 16899617Read ↗

Targeting EGFR in bladder cancer.Semantic proximity Read ↗

Identification of G2607A mutation in EGFR gene with a significative rate in Moroccan patients with Bladder Cancer.Semantic proximity Read ↗

High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues.Semantic proximity Read ↗

Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target?Semantic proximity Read ↗

Epidermal growth factor receptor domain II, IV, and kinase domain mutations in human solid tumors.Semantic proximity Read ↗

PIK3CA Mutational Analysis in Formalin-Fixed, Paraffin-Embedded Archival Tissues of Urothelial Carcinoma of Urinary BladderSemantic proximity Read ↗

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer.Semantic proximity Read ↗

Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR.Semantic proximity Read ↗

Somatic Mutations of<i>EGFR</i>in Colorectal Cancers and GlioblastomasSemantic proximity Read ↗

Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors.Semantic proximity Read ↗

Genetic alterations of p16INK4a and p14ARF genes in human bladder cancer.Semantic proximity Read ↗

Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.